Soligenix (NASDAQ:SNGX) Releases Earnings Results, Misses Expectations By $0.19 EPS

Soligenix (NASDAQ:SNGX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19), Zacks reports. Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The business had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.20 million. During the same quarter last year, the firm posted ($12.66) EPS.

Soligenix Trading Up 0.4 %

Soligenix stock opened at $2.39 on Friday. Soligenix has a 52 week low of $1.83 and a 52 week high of $14.92. The stock has a market cap of $6.00 million, a P/E ratio of -0.32 and a beta of 2.03. The stock has a 50 day moving average of $2.37 and a 200-day moving average of $3.12.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.